Le professeur Louis Dubertret, ex-président de la fondation René Touraine, nous explique les fausses opinions qu’accompagnent souvent un individu atteint par la maladie.
Le psoriasis est-il contagieux ?
Non. Vous pouvez, par exemple, aller à la piscine avec du psoriasis sans aucun risque. Au contraire, la peau psoriasique, avec ses plaques, contient bien plus de molécules anti-infectieuses qu’une peau normale. Il s’agit donc d’une peau qui s’infecte beaucoup moins qu’une autre.
Le psoriasis est-il héréditaire ?
Ce question est récurrente car le psoriasis a une origine génétique. Cependant, cette transmission se réalise non pas de manière mathématique ou monogénique, mais bien comme un "terrain" favorable aux membres d’une même famille. De la même manière qu’une mère atteinte régulièrement de rhumes des foins a des enfants qui présentent le risque de le développer, un parent atteint de psoriasis aura des enfants risquant de developper cette pathologie plus que la moyenne. Cette inquiétude se retrouve souvent chez un futur parent souffrant de psoriasis sévère. Mais il faut savoir que dans ce cas-là, le mélange de ses gènes avec ceux de l’autre parent ne peut, au pire, qu’entraîner un psoriasis plus modéré chez l’enfant. Aussi, le développement de traitements de plus en plus efficaces doit nous faire sortir de la vision du psoriasis comme une malédiction transmise de génération en génération.
Si mon traitement ne me convient pas, dois-je changer de médecin ?
En raison de ses symptômes variables pour chaque individu, le psoriasis fait partie de ces maladies où le patient dispose d’informations précieuses sur sa condition que le médecin ne peut connaître. De ce fait, le patient doit les lui communiquer régulièrement afin de bénéficier d’un ajustement continu de son traitement permettant de l’améliorer dans le temps. Changer perpétuellement de médecin est donc une erreur puisque cela compromet l’efficacité des soins. Il vaut donc mieux avoir la patience d’expliquer à son médecin de départ les causes de son insatisfaction afin que ce dernier, essai après essai, trouve le traitement idéal. Cela est d’autant plus important qu’aucun médecin ne peut tout savoir, surtout dans le cas d’une maladie s’exprimant différemment chez chaque personne.
SPIN Presentation
Recent news
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
- 2019/04/17 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P et al.
JAK-inhibitors in dermatology: current evidence and future applications.
J Dermatolog Treat.
2019 Nov , 30, (7):648-658.
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti-inflammatory properties and have been approved in many countries for the treatment of rheumatoid arthritis (tofacitinib, baricitinib) and myelofibrosis or polycythemia vera (ruxolitinib). The aim of the publication was to summarize and critically analyze the efficacy and safety of JAK-inhibitors in skin diseases, such (...)
see on pubmed
Patient preferences for attributes of topical anti-psoriatic medicines.
Vasconcelos V et al.
Patient preferences for attributes of topical anti-psoriatic medicines.
J Dermatolog Treat.
2019 Nov , 30, (7):659-663.
Patient preferences should be considered when prescribing topical treatments to drive up adherence and improve clinical outcomes. The aim of this work was to identify the most important attributes of topical medicines for psoriasis treatment in the patients' view, and explore the sociodemographic and clinical determinants of these preferences. A questionnaire for the evaluation of the relevancy given to specific attributes of topical medicines used for psoriasis treatment was developed (...)
see on pubmed
Salidroside inhibits MAPK, NF-κB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation.
Redox Rep..
2019 Dec , 24, (1):70-74.
To unveil the role of SIRT1 in limiting oxidative stress in psoriasis and to further discuss the therapeutic prospects of salidroside in psoriasis. Literature from 2002 to 2019 was searched with "psoriasis", "oxidative stress", "SIRT1", "salidroside" as the key words. Then, Oxidative stress in psoriasis and the role of SIRT1 were summarized and the potential role of salidroside in the disease was speculated. Oxidative stress might contribute to the pathogenesis of psoriasis. High levels (...)
see on pubmed
on Atopic Dermatitis
A case of infective endocarditis associated with atopic dermatitis perioperatively treated with dupilumab.
J Dermatolog Treat.
2019 Nov , 30, (7):674-676.
Several case reports and reviews support a relationship between atopic dermatitis (AD) and infective endocarditis (IE). Here, we present a case of severe AD suspected of causing IE. A 21-year-old man with severe AD was admitted to our hospital due to unidentified fever, syncope, and headache. He was diagnosed with IE with cerebral embolism and mitral regurgitation. Before elective cardiac surgery, he was subcutaneously administered dupilumab for 2 months to control AD. Dupilumab improved (...)
see on pubmed
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
Choi EJ et al.
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
J Enzyme Inhib Med Chem.
2019 Dec , 34, (1):613-619.
This study aimed to evaluate the effects of cinnamamides on atopic dermatitis (AD) and the mechanisms underlying these effects. To this end, the actions of two cinnamamides, (E)-3-(4-hydroxyphenyl)-N-phenylethyl acrylamide (NCT) and N-trans-coumaroyltyramine (NCPA), were determined on AD by orally administering them to mice. Oral administration of the cinnamamides ameliorated the increase in epidermal and dermal thickness as well as mast cell infiltration. Cinnamamides suppressed serum (...)
see on pubmed
Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Artif Cells Nanomed Biotechnol.
2019 Dec , 47, (1):3540-3547.
Allergen-specific immunotherapy is widely used for allergic rhinitis and asthma treatment worldwide. This study explored the efficacy and safety of sublingual immunotherapy (SLIT) with the extracts of ( Drops) on house dust mites (HDM)-induced atopic dermatitis (AD). 239 patients with HDM-induced AD were recruited and exposure to a multi-centre, randomized, double-blind, and placebo-controlled clinical trials for 36 weeks, which were randomly divided into placebo and sublingual Drops (...)
see on pubmed
